Entwicklung eines experimentellen Systems zur Untersuchung der subzellulärenLokalisierung der Alpha-Methylacyl-CoA-Racemase (AMACR) (Methode der retroviralen Transfektion von transformierten, embryonalen Mausfibroblasten) / Development of a experimental system for the investigation of the subcellular localisation of alpha-methylacyl-CoA racemase (amacr) (retroviral transfection of mouse fibroblasts)

Im Katabolismus methylverzweigter Fettsäuren spielt die alpha-Methylacyl-CoA-Racemase eine wichtige Rolle, indem sie die (R)- und (S)-Isomere von alpha-methylverzweigten Fettsäuren als Coenzym A Thioester racemisiert. Methylverzweigte Fettsäuren entstehen beim Abbau von Isoprenoiden und werden darüber hinaus auch von vielen Organismen, wie z.B. Mycobakterien, synthetisiert. Die Hauptaufgabe der Racemase ist aber vermutlich in der Biosynthese von Gallensäuren zu sehen. Das Ziel der vorliegenden Arbeit war es, die alpha-Methylacyl-CoA-Racemase aus humanem Gewebe zu reinigen und zu charakterisieren sowie ihre physiologische Rolle im Katabolismus verzweigtkettiger Fettsäuren und der Gallensäurebiosynthese zu untersuchen. Die alpha-Methylacyl-CoA-Racemase wurde aus humanem Gewebe zur Homogenität gereinigt, umfassend biochemisch charakterisiert und zur genauen molekularbiologischen Analyse in E.coli kloniert. Die Aktivität der Racemase wurde anhand der [³H]H2O-Freisetzung aus [alpha-³H]-a-Methylacyl-CoAs bestimmt. Die humane Racemase ist in der aktiven Form ein monomeres Protein und besteht aus 382 Aminosäuren. Als Substrate akzeptiert das Enzym ein breites Spektrum von alpha-Methylacyl-CoAs. Neben den Coenzym A-Thioestern alpha-methylverzweigter Fettsäuren, wie Pristansäure, werden auch CoA-Ester von Steroidderivaten, z.B. des Gallensäureintermediats Trihydroxycoprostansäure, und aromatischen Phenylpropionsäuren, wie dem Analgetikum Ibuprofen, umgesetzt. Freie Fettsäuren, geradkettige oder beta-methylverzweigte Acyl-CoAs werden nicht racemisiert. Die alpha-Methylacyl-CoA-Racemase ist im Menschen zu ca. 80 Prozent auf die Peroxisomen und ca. 20 Prozent auf die Mitochondrien verteilt, wobei entsprechende peroxisomale (PTS 1) und mitochondriale (MTS) Transportsignale die Lokalisation bestimmen. Die vollständige cDNA-Sequenz der humanen a-Methylacyl-CoA-Racemase hat eine Gesamtlänge von 2039 Basenpaaren mit einem offenen Leseraster von 89 - 1237 bp. Das Startcodon ATG ist in eine klassische Kozak-Sequenz zum Translationsstart eingebettet. Die Protein endet am C-Terminus mit dem Sequenzmotiv –KASL, das dem peroxisomalen Transportsignal (PTS I) einiger Säugetierkatalasen entspricht. Aufgrund alternativer Polyadenylierung sind in allen untersuchten menschlichen Geweben Transkripte von 1,6 kb bzw. 2,0 kb zu finden. Es liegt keine gewebsabhängige Polyadenylierung vor, die Racemase wird aber gewebsspezifisch exprimiert (besonders stark in Leber und Niere). Das humane Racemasegen liegt auf dem kurzen Arm des Chromosoms 5 nahe am Centromer (5p1.3), im Intervall von D5S651 (46,6 cM) und D5S634 (59.9 cM). / Racemization is an essential step for bile acid synthesis and it is important for degradation of alpha-methyl branched-chain fatty acids. The (R)- and (S)-isomers of alpha-methyl-branched chain fatty acids were shown to be interconverted as coenzyme A thioesters by an alpha-methylacyl-CoA racemase. Various branched-chain fatty acids arise in the catabolism of isoprenoids and are also synthesized by a variety of organisms, particularly mycobacteria. The aim of this work was to purify and to characterize the racemase from human tissue and to analyse the physiological role in the degradation of branched-chain fatty acids and the bile acid synthesis. The alpha-methylacyl-CoA racemase was purified from human liver to apparent homogeneity. The enzyme was exhaustively characterized by methods of biochemistry and protein chemistry. The cDNA coding for human racemase was cloned in E. coli and sequenced. A radiometric assay with 2-methyl[2-³H]acyl-CoAs as substrates was used routinely for monitoring purification procedure. The active form of the enzyme is a monomeric protein comprising 382 amino acids. The enzyme accepts a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis) as substrates. Also arylpropionyl-CoAs such as the anti-inflammatory drug ibuprofen are accepted, but neither free fatty acids, beta-methyl-branched nor linear-chain acyl-CoAs. In human tissues 80 - 90 Prozent of the racemase activity is found in peroxisomes and 10 - 20 Prozent in mitochondria. Degradation of branched chain fatty acids is located in both compartments, so the enzyme has to be distributed between peroxisomes and mitochondria. No evidence was found for the existence of isoenzymes or different transcription products. It appears that only one mRNA is transcribed from one gene and that also only one protein is synthesized. The different recognition of peroxisomal (PTS 1) and mitochondrial targeting signals (MTS) may determine the subcellular distribution. The complete cDNA sequence has an overall length of 2039 base pairs, with a open reading frame between 89 - 1237 bp. The ATG start codon is embedded in a classical Kozak sequence for translation start. The C-Terminus of the protein is –KASL, which is very similar to the peroxisomal targeting signals (PTS 1) of many mammalian catalases. In all human tissues analysed in this work two different transcripts of racemase with sizes of 1,6 kb and 2,0 kb have been found and show alternate polyadenylation. Polyadenylation of racemase is not tissue-dependent but its expression is tissue-specific (strong activity is found in liver and kidney). The human racemase gene is localized on the short arm of chromosome 5, near the centromer (region 5p1.3) and between the markers D5S651 (46,6 cM) and D5S634 (59.9 cM).

Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding microRNAs (miRNA). Methods: In silico analyses were used to search for miRNAs being putative regulators of PCa-associated genes. The expression of nine selected miRNAs (hsa-miR-101, -138, -186, -224, -26a, -26b, -374a, -410, -660) as well as of the aforementioned PCa-associated genes was analyzed by quantitative PCR using 50 malignant (Tu) and matched non-malignant (Tf) tissue samples from prostatectomy specimens as well as 30 samples from patients with benign prostatic hyperplasia (BPH). Then, correlations between paired miRNA and target gene expression levels were analyzed. Furthermore, the effect of exogenously administered miR-26a on selected target genes was determined by quantitative PCR and Western Blot in various PCa cell lines. A luciferase reporter assay was used for target validation. Results: The expression of all selected miRNAs was decreased in PCa tissue samples compared to either control group (Tu vs Tf: -1.35 to -5.61-fold; Tu vs BPH: -1.17 to -5.49-fold). The down-regulation of most miRNAs inversely correlated with an up-regulation of their putative target genes with Spearman correlation coefficients ranging from -0.107 to -0.551. MiR-186 showed a significantly diminished expression in patients with non-organ confined PCa and initial metastases. Furthermore, over-expression of miR-26a reduced the mRNA and protein expression of its potential target gene AMACR in vitro. Using the luciferase reporter assay AMACR was validated as new target for miR-26a. Conclusions: The findings of this study indicate that the expression of specific miRNAs is decreased in PCa and inversely correlates with the up-regulation of their putative target genes. Consequently, miRNAs could contribute to oncogenesis and progression of PCa via an altered miRNA-target gene-interaction.

Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding microRNAs (miRNA). Methods: In silico analyses were used to search for miRNAs being putative regulators of PCa-associated genes. The expression of nine selected miRNAs (hsa-miR-101, -138, -186, -224, -26a, -26b, -374a, -410, -660) as well as of the aforementioned PCa-associated genes was analyzed by quantitative PCR using 50 malignant (Tu) and matched non-malignant (Tf) tissue samples from prostatectomy specimens as well as 30 samples from patients with benign prostatic hyperplasia (BPH). Then, correlations between paired miRNA and target gene expression levels were analyzed. Furthermore, the effect of exogenously administered miR-26a on selected target genes was determined by quantitative PCR and Western Blot in various PCa cell lines. A luciferase reporter assay was used for target validation. Results: The expression of all selected miRNAs was decreased in PCa tissue samples compared to either control group (Tu vs Tf: -1.35 to -5.61-fold; Tu vs BPH: -1.17 to -5.49-fold). The down-regulation of most miRNAs inversely correlated with an up-regulation of their putative target genes with Spearman correlation coefficients ranging from -0.107 to -0.551. MiR-186 showed a significantly diminished expression in patients with non-organ confined PCa and initial metastases. Furthermore, over-expression of miR-26a reduced the mRNA and protein expression of its potential target gene AMACR in vitro. Using the luciferase reporter assay AMACR was validated as new target for miR-26a. Conclusions: The findings of this study indicate that the expression of specific miRNAs is decreased in PCa and inversely correlates with the up-regulation of their putative target genes. Consequently, miRNAs could contribute to oncogenesis and progression of PCa via an altered miRNA-target gene-interaction.